Atty. Dkt. No. 034827-1401

REMARKS

Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow. The specification has been amended to conform trademark identification to Patent Office policy and to add SEQ ID NOs to what is identified in the specification as Figures 1 and 2 found on pages 33 and 34, respectively. Accordingly, the amendments to the specification and claims raise no issue of new matter.

Claims 1-16 and 18 have been cancelled without prejudice or disclaimer. Applicant retains the right to pursue cancelled subject matter in subsequent divisional or continuation applications claiming priority to the instant application. The only claims presently pending have been deemed allowable by the examiner. Accordingly, Applicant respectfully submits that the case in condition for immediate allowance.

SPECIFICATION

Applicant has amended reference to BioTek in the specification to BIOMEK® 2000 as requested by the Examiner. Accordingly, this issue has been fully addressed.

REJECTION UNDER 35 USC § 112, SECOND PARAGRAPH

The rejection of claims 1-16 and 18 under 35 USC § 112, second paragraph for allegedly being indefinite for recitation of "TIGR" is respectfully traversed. Although Applicant does not agree with the basis for this rejection, the claims have been cancelled without prejudice in order to advance prosecution of the case. Accordingly, the rejection has been rendered moot.

REJECTION UNDER 35 USC § 102

The rejection of claims 1-3, 5-11, 13-16 and 18 under 35 USC § 102(b) as being allegedly anticipated by Stone et al. (U.S. 5,925,748) is respectfully traversed. Although Applicant does not agree with the basis for this rejection, the claims have been cancelled without prejudice in order to advance prosecution of the case. Accordingly, the rejection has been rendered moot.

Atty. Dkt. No. 034827-1401

REJECTION UNDER 35 USC § 102

The rejection of claims 1-3, 5-11, 13-16 and 18 under 35 USC § 102(e) as being allegedly anticipated by Nguyen et al. (U.S. 6,475,724) is respectfully traversed. Although Applicant does not agree with the basis for this rejection, the claims have been cancelled without prejudice in order to advance prosecution of the case. Accordingly, the rejection has been rendered moot.

Applicant believes that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872. ed, UFF/C/A/

Respectfully submitted,

Barry S. Wilson

Attorney for Applicant Registration No. 39,431

Date August 21, 2003 By 15am

FOLEY & LARDNER Customer Number: 30542

Telephone:

(858) 847-6722

Facsimile:

(858) 792-6773

Received from < > at 8/21/03 6:21:44 PM [Eastern Daylight Time]



UNITED STATE DEPARTMENT OF COMMERCE Pat nt and Tr. mark Offic Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO /TITLE

10/017,870

12/12/2001

034827-1401

DATE MAILED:

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821–1.825 for the following reason(s):

		ribed for the following reason(s).
1. This application fails to	comply with the requirements of 37 CF	FR 1.821–1.825.
2. This application does no "Sequence Listing" as re	ot contain, as a separate part of the dis equired by 37 CFR 1.821(c).	sclosure on paper copy, a
3. A copy of the "Sequence by 37 CFR 1.821(e).	e Listing" in computer readable form h	as not been submitted as required
Or the computer readable	e Listing" in computer readable form he e form, however, does not comply with ndicated on the attached marked—up o	the requirements of 27 CED
5. The computer readable damaged and/or unread substitute computer read	form that has been filed with this appli able as Indicated on the attached CRF dable form must be submitted as requi	cation has been found to be F Diskette Problem Report. A ired by 37 CFR 1.825(d).
_	Sequence Listing* Is not the same as to	
17. OTHER: FIGURES	1-2 contain nucleot	
A statement that the cor	omputer readable form (CRF) copy of aper copy of the "Sequence Listing," a catlon. Itent of the paper and computer readalew matter, as required by 37 CFR 1.82	this conian are the same and where
For CRF submission he	G COMPLIANCE WITH THESE REQU , call (703) 308–1123. lp, call (703) 308–4212. elp, call (703) 308–6856.	DOCKETED
·		MAY 2 7 2003
Customer Service Center Initial Patent Examination Division	on (703) 308–1202	634827-1401
FORMPTO-1661(Rev. 7/97)	PART 1 - ATTORNEY/APPLICANT COPY	Due 8-21-03